Purpose: Periodic discharges in EEG and a history of rapidly progressive dementia are known to be associated with sporadic Creutzfeld-Jakob Disease (sCJD). Doubts regarding this rare but fatal diagnosis can arise, when episodic symptoms (seizures, psychiatric features, speech disturbances) are present and the EEG shows epileptiform discharges within this periodicity. This scenario may indicate nonconvulsive status epilepticus (NCSE), which is -in contrast to sCJD -a treatable and frequent condition. Methods: Herein we report a small retrospective study of 4 elderly patients, who suffered from sCJD, but due to episodic symptoms and benzodiazepine-responsive epileptiform discharges in combination to a subacute cognitive decline, NCSE was considered as a potential differential diagnosis and therefore treated aggressively. Results: Ultimately, this treatment was not successful and sCJD was diagnosed in all cases. Hence, there was no diagnostic and prognostic value of abolishing periodic discharges in EEG via benzodiazepines in differentiating sCJD from NCSE in our series. Conclusion: These findings indicate that periodic discharges in sCJD can be responsive to benzodiazepines andnot necessarily help to differentiate differentiation between sCJD and NCSE of other causes. We argue that an aggressive anticonvulsive treatment in this scenario should be considered cautiously, especially for invasive options like general anesthesia.
Introduction
In clinical neurology, EEG is a widely-used method for acquiring functional information of the brain, particularly if epileptic or nonepileptic seizures are considered. However, there are pitfalls and limitations especially when periodic discharges are apparent. These can indicate an epileptic phenomenon or be due to (severe) metabolic processes, hypoxic brain damage or neurodegeneration.
Periodic discharges (frequency: 0,5-2 per second, duration: 100-600 ms, amplitude 150 mV-300 mV, localization: usually generalized, but lateralized or regional possible) are a hallmark of sporadic Creutzfeld-Jakob-Disease (sCJD) and occur, in median, 12 weeks after the first symptoms typically together with the appearance of myoclonia. Periodic discharges have a sensitivity of 67% and specificity of 86% among other progressive dementias [1] . In contrast, EEG patterns in non-convulsive status epilepticus (NCSE) do not have such a clear definition and are characterized by continuous or intermittent focal or generalized spikes, sharp waves, sharp-and-slow complexes <3 Hz with EEG and clinical improvement after anticonvulsive therapy [2] .
Although strong epidemiological data are lacking, NCSE presents 20% of all patients with status epilepticus (150.000 individuals with status epilepticus annually in the US), making this Abbreviations: sCJD, sporadic Creutzfeld-Jakob Disease; NCSE, non-convulsive status epilepticus; CSF, cerebrospinal fluid; EEG, electroencephalogram; cMRI, cerebral magnet resonance imaging.a very common diagnosis in clinical neurology [3] . The incidence might even be higher, given that this condition is probably underdiagnosed in critically ill patients [4] . In clinical practice, the responsiveness to benzodiazepines is frequently used to differentiate epileptic processes, in particular NCSE, from other nonepileptic causes. Benzodiazepine-responsiveness of periodic discharges during EEG-examination helps predicting recovery of consciousness in clinically suspected NCSE, but only if accompanied by concomitant clinical improvement after benzodiazepine administration, as shown for critically ill patients [4] or metabolic encephalopathies [5] .
Treatable disorders, like NCSE, are important clinical differential diagnoses especially in contrast to sCJD, which still has no effective treatment options. However, the risk of overtreatment is present. Here we report a series of four patients suspected of having NCSE eventually diagnosed as sCJD.
Methods/patients
4 patients (3 male, 1 female, mean age 71 years, see Table 1 ) were admitted to the university hospitals of Marburg and Tübingen (Germany) between 2005 and 2015 for evaluation of rapid progressive dementia. All patients were examined by at least two experienced neurologists and history about additional symptoms was taken from relatives. All patients had repeated EEG examinations (n > 5 per each patient, mean time course 1-3 months), at least two cMRI and CSF-studies were done. During EEG examinations patients received 2 mg of lorazepam and subsequently further anticonvulsive treatment (Table 1) . Postmortal brain autopsy was taken in 3 of 4 cases.
Results
In addition to rapid progressive dementia, all patients (Table 1) showed episodic symptoms as follows: Patient 1 showed recurrent aphasia, right-sided hemiplegia, and relatives reported generalized tonic clonic seizures. Patient 2 showed episodic states of gazing between 30 s and one minute, balance problems and myoclonia of different body parts. Patient 3 showed recurrent aphasia and myoclonia of different body parts. Patient 4 showed a panic disorder, a slowly progressive aphasia, a permanent hemiplegia of the right body half and myoclonia of the left body half. All patients did not suffer from prior relevant brain diseases (e.g. epilepsy, stroke, head trauma, etc.). In all patients, the repeated EEG examinations (n > 5 per each patient, mean time course 1-3 months) showed continuous periodic epileptiform, compatible with NCSE, and non-epileptiform discharges, compatible with sCJD, which both were abolished by acute benzodiazepine administration during the EEG-examination (criteria as above mentioned, see Fig. 1 for representative EEG before and after benzodiazepine-administration).
Due to the combination of a subacute cognitive decline, episodic symptoms and benzodiazepine-responsive periodic discharges, the differential diagnosis of NCSE and, hence, treatability was considered which resulted in an aggressive anticonvulsive treatment, including propofol anesthesia in 3 of 4 cases. Neither a clinical nor consistent "improvement" of the EEG-findings were achieved. Multiple cMRI were performed during the individual disease courses, unravelling cortical and subcortical diffusion restrictions. Cerebral spinal fluid (CSF) studies showed normal cell, protein, lactate and glucose levels in all cases. CSF tau levels were above 1000 pg/ml in 3 of 4 cases, and 14-3-3 protein levels were elevated in 2 of 3 patients.
All patients died 3 to 4 months after the first clinical symptoms. Death took place irrespective to discontinuation or continuation of the anticonvulsive treatment. Autopsy was performed in 3 of 4 cases and confirmed the diagnosis of sCJD. In one patient autopsy was declined, but sCJD was probable due to clinical signs of myoclonia, akinetic mutism, auxiliary findings of elevated 14-3-3-levels in CSF, typical periodic discharges in EEG and typical subcortical and cortical diffusion restrictions in cMRI [6] . Genetic testing for possible genetic inheritance of prion disease was not performed.
Discussion
We report a small retrospective study of 4 patients with sCJD (3 autopsy confirmed), who were initially considered as possible NCSE. This was based on the combination of a subacute cognitive decline, episodic symptoms and benzodiazepine-responsive periodic epileptiform discharges in the EEG.
Other diagnostic approaches (mainly cMRI and/or CSF-studies) did not help to clearly differentiate between acute cell damage due to status epilepticus or sCJD. It is known that both conditions can result in DWI-abnormalities (usually diffusion restriction) in cMRI. Milligan et al. [7] showed in a small retrospective study that 5 of 10 epilepsy patients had DWI-abnormalities in the thalamus and at least one cortical region due to NCSE. In sCJD, DWI abnormalities in the same regions are reported to have a sensitivity of 98% and a specificity of 71% compared to between clinically possible versus probable sCJD patients. These results led to inclusion of DWIabnormalities as additional diagnostic criteria for sCJD [6] . The same diagnostic ambiguity is present for elevated CSF Tau and 14-3-3 levels, indicating rapid neuronal cell death irrespective of the cause. CSF Tau levels in 40 patients with NCSE À although on average 317 pg/ml À can reach up to 2533 pg/ml (n = 3) [8] and 14-3-3 has been reported to be elevated in NCSE [9] . Tau levels above 1300 pg/ml and 14-3-3 are reported to have a sensitivity of 92% and specificity of 71% for sCJD [10] . To our knowledge, the benzodiazepine-responsiveness of rhythmic EEG discharges in sCJD is unclear.
There have been a few case-series and reports [11] , which postulate the coexistence of simultaneously NCSE and sCJD based on reported seizures and periodic epileptiform discharges in EEG. A "structural epilepsy" due to the underlying sCJD as a severe form of acute encephalopathy might explain the similar results of EEG, cMRI and CSF studies. This presumption is supported by the observation that other (metabolic) encephalopathies can lead to status epilepticus [12] . Nevertheless, we argue that anticonvulsive treatment of elderly patients with a subacute cognitive decline and benzodiazepine-responsive periodic discharges has only limited clinical value when sCJD is the most likely diagnosis. Invasive treatment protocols like propofol anesthesia or numerous trials of anticonvulsive drugs over extended periods of time should be avoided in this scenario. Our results are in keeping with the observation that the underlying cause is the most crucial prognostic factor when status epilepticus is considered.
Conclusion
Periodic discharges in sCJD can be responsive to benzodiazepines and can cause problems in differentiating NCSE and sCJD. An aggressive anticonvulsive treatment in sCJD has limited clinical value and should not be expanded into invasive treatment protocols like propofol anesthesia.
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